Hammond, J. et al. Oral nirmatrelvir for high-risk, nonhospitalized adults with covid-19. N. Engl. J. Med. 386, 13971408. https://doi.org/10.1056/NEJMoa2118542 (2022).
Article CAS PubMed Google Scholar
Gottlieb, R. L. et al. Early remdesivir to prevent progression to severe covid-19 in outpatients. N. Engl. J. Med. 386, 305315. https://doi.org/10.1056/NEJMoa2116846 (2022).
Article CAS PubMed Google Scholar
RECOVERY Collaborative Group et al. Dexamethasone in hospitalized patients with covid-19. N. Engl. J. Med. 384, 693704. https://doi.org/10.1056/NEJMoa2021436 (2021).
Article Google Scholar
The Writing Committee for the REMAP-CAP Investigators. Effect of hydrocortisone on mortality and organ support in patients with severe COVID-19: The remap-cap COVID-19 corticosteroid domain randomized clinical trial. JAMA 324, 13171329. https://doi.org/10.1001/jama.2020.17022 (2020).
Article CAS PubMed Central Google Scholar
Cano, E. J. et al. Impact of corticosteroids in coronavirus disease 2019 outcomes: Systematic review and meta-analysis. Chest 159, 10191040. https://doi.org/10.1016/j.chest.2020.10.054 (2021).
Article CAS PubMed Google Scholar
REMAP-CAP Investigators et al. Interleukin-6 receptor antagonists in critically ill patients with covid-19. N. Engl. J. Med. 384, 14911502. https://doi.org/10.1056/NEJMoa2100433 (2021).
Article Google Scholar
Kalil, A. C. et al. Baricitinib plus remdesivir for hospitalized adults with covid-19. N. Engl. J. Med. 384, 795807. https://doi.org/10.1056/NEJMoa2031994 (2021).
Article CAS PubMed Google Scholar
Chen, P. et al. SARS-CoV-2 neutralizing antibody LY-CoV555 in outpatients with covid-19. N. Engl. J. Med. 384, 229237. https://doi.org/10.1056/NEJMoa2029849 (2021).
Article CAS PubMed Google Scholar
Weinreich, D. M. et al. REGN-COV2, a neutralizing antibody cocktail, in outpatients with covid-19. N. Engl. J. Med. 384, 238251. https://doi.org/10.1056/NEJMoa2035002 (2021).
Article CAS PubMed Google Scholar
COVID-19 Treatment Guidelines Panel. Statement on Tixagevimab Plus Cilgavimab (Evusheld) as Pre-Exposure Prophylaxis of COVID-19. Coronavirus Disease (COVID-19) Treatment Guidelines (2023, accessed 4 Apr 2023). https://www.covid19treatmentguidelines.nih.gov/therapies/statement-on-evusheld/.
Janiaud, P. et al. Association of convalescent plasma treatment with clinical outcomes in patients with COVID-19: A systematic review and meta-analysis. JAMA 325, 11851195. https://doi.org/10.1001/jama.2021.2747 (2021).
Article CAS PubMed Google Scholar
Joyner, M. J. et al. Convalescent plasma antibody levels and the risk of death from covid-19. N. Engl. J. Med. 384, 10151027. https://doi.org/10.1056/NEJMoa2031893 (2021).
Article CAS PubMed Google Scholar
FDA News Release. FDA issues emergency use authorization for convalescent plasma as potential promising COVID19 treatment, another achievement in administrations fight against pandemic (2023, accessed 4 Apr 2023). https://www.fda.gov/news-events/press-announcements/fda-issues-emergency-use-authorization-convalescent-plasma-potential-promising-covid-19-treatment.
FDA In Brief: FDA updates emergency use authorization for COVID-19 convalescent plasma to reflect new data (2023, accessed 4 Apr 2023). https://www.fda.gov/news-events/fda-brief/fda-brief-fda-updates-emergency-use-authorization-covid-19-convalescent-plasma-reflect-new-data.
COVID-19 Treatment Guidelines Panel. COVID-19 Treatment Guidelines: COVID-19 Convalescent Plasma (2023, accessed 15 Sep 2023). https://www.covid19treatmentguidelines.nih.gov/therapies/antivirals-including-antibody-products/covid-19-convalescent-plasma/.
Centers for Disease Control and Prevention. COVID Data Tracker, COVID-19 Vaccinations in the United States (2023, accessed 3 Mar 2023). https://covid.cdc.gov/covid-data-tracker/#vaccinations_vacc-people-booster-percent-pop5.
Sun, C., Pleyer, C. & Wiestner, A. COVID-19 vaccines for patients with haematological conditions. Lancet Haematol. 8, e312e314. https://doi.org/10.1016/S2352-3026(21)00073-9 (2021).
Article CAS PubMed PubMed Central Google Scholar
Herishanu, Y. et al. Efficacy of the BNT162b2 mRNA COVID-19 vaccine in patients with chronic lymphocytic leukemia. Blood 137, 31653173. https://doi.org/10.1182/blood.2021011568 (2021).
Article CAS PubMed PubMed Central Google Scholar
Harvey, R. A. et al. Association of SARS-CoV-2 seropositive antibody test with risk of future infection. JAMA Intern. Med. 181, 672679. https://doi.org/10.1001/jamainternmed.2021.0366 (2021).
Article CAS PubMed PubMed Central Google Scholar
Biernat, M. M. et al. Early administration of convalescent plasma improves survival in patients with hematological malignancies and COVID-19. Viruses 13, 436. https://doi.org/10.3390/v13030436 (2021).
Article CAS PubMed PubMed Central Google Scholar
Avouac, J. et al. COVID-19 outcomes in patients with inflammatory rheumatic and musculoskeletal diseases treated with rituximab: A cohort study. Lancet Rheumatol. 3, e419e426. https://doi.org/10.1016/S2665-9913(21)00059-X (2021).
Article CAS PubMed PubMed Central Google Scholar
Hensley, M. K. et al. Intractable coronavirus disease 2019 (COVID-19) and prolonged severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) replication in a chimeric antigen receptor-modified T-cell therapy recipient: A case study. Clin. Infect. Dis. 73, e815e821. https://doi.org/10.1093/cid/ciab072 (2021).
Article CAS PubMed PubMed Central Google Scholar
Lancman, G., Mascarenhas, J. & Bar-Natan, M. Severe COVID-19 virus reactivation following treatment for B cell acute lymphoblastic leukemia. J. Hematol. Oncol. 13, 131. https://doi.org/10.1186/s13045-020-00968-1 (2020).
Article CAS PubMed PubMed Central Google Scholar
Hughes, C. M. et al. Clinical illness with viable severe acute respiratory coronavirus virus 2 (SARS-CoV-2) virus presenting 72 days after infection in an immunocompromised patient. Infect. Control Hosp. Epidemiol. 43, 820822. https://doi.org/10.1017/ice.2021.120 (2022).
Article CAS PubMed Google Scholar
Vardhana, S. A. & Wolchok, J. D. The many faces of the anti-COVID immune response. J. Exp. Med. 217, e20200678. https://doi.org/10.1084/jem.20200678 (2020).
Article CAS PubMed PubMed Central Google Scholar
Rutherford, M. A. et al. Risk factors for severe outcomes in patients with systemic vasculitis and COVID-19: A binational, registry-based cohort study. Arthrit. Rheumatol. 73, 17131719. https://doi.org/10.1002/art.41728 (2021).
Article CAS Google Scholar
Kim, J. S. et al. Clinical characteristics and mortality of patients with hematologic malignancies and COVID-19: A systematic review. Eur. Rev. Med. Pharmacol. Sci. 24, 1192611933. https://doi.org/10.26355/eurrev_202011_23852 (2020).
Article CAS PubMed Google Scholar
Vijenthira, A. et al. Outcomes of patients with hematologic malignancies and COVID-19: A systematic review and meta-analysis of 3377 patients. Blood 136, 28812892. https://doi.org/10.1182/blood.2020008824 (2020).
Article CAS PubMed PubMed Central Google Scholar
Sharma, A. et al. Clinical characteristics and outcomes of COVID-19 in haematopoietic stem-cell transplantation recipients: An observational cohort study. Lancet Haematol. 8, e185e193. https://doi.org/10.1016/S2352-3026(20)30429-4 (2021).
Article CAS PubMed PubMed Central Google Scholar
Kenig, A., Ishay, Y., Kharouf, F. & Rubin, L. Treatment of B-cell depleted COVID-19 patients with convalescent plasma and plasma-based products. Clin. Immunol. 227, 108723. https://doi.org/10.1016/j.clim.2021.108723 (2021).
Article CAS PubMed PubMed Central Google Scholar
Hueso, T. et al. Convalescent plasma therapy for B-cell-depleted patients with protracted COVID-19. Blood 136, 22902295. https://doi.org/10.1182/blood.2020008423 (2020).
Article CAS PubMed Google Scholar
Ferrari, S., Caprioli, C., Weber, A., Rambaldi, A. & Lussana, F. Convalescent hyperimmune plasma for chemo-immunotherapy induced immunodeficiency in COVID-19 patients with hematological malignancies. Leuk. Lymphom. 62, 14901496. https://doi.org/10.1080/10428194.2021.1872070 (2021).
Article CAS Google Scholar
Thompson, M. A. et al. Association of convalescent plasma therapy with survival in patients with hematologic cancers and COVID-19. JAMA Oncol. 7, 11671175. https://doi.org/10.1001/jamaoncol.2021.1799 (2021).
Article PubMed PubMed Central Google Scholar
Gerber, V. et al. Protracted SARS-CoV-2 pneumonia with rituximab treatment: About two cases. J. Med. Virol. 93, 41414144. https://doi.org/10.1002/jmv.26921 (2021).
Article CAS PubMed PubMed Central Google Scholar
Hamilton, F. W., Lee, T., Arnold, D. T., Lilford, R. & Hemming, K. Is convalescent plasma futile in COVID-19? A Bayesian re-analysis of the RECOVERY randomized controlled trial. Int. J. Infect. Dis. 109, 114117. https://doi.org/10.1016/j.ijid.2021.06.034 (2021).
Article CAS PubMed PubMed Central Google Scholar
Senefeld, J. W. et al. Use of convalescent plasma in COVID-19 patients with immunosuppression. Transfusion 61, 25032511. https://doi.org/10.1111/trf.16525 (2021).
Article CAS PubMed PubMed Central Google Scholar
Senefeld, J. W. et al. COVID-19 convalescent plasma for the treatment of immunocompromised patients: A systematic review and meta-analysis. JAMA Netw. Open 6, e2250647. https://doi.org/10.1001/jamanetworkopen.2022.50647 (2023).
Article PubMed PubMed Central Google Scholar
von Elm, E. et al. The strengthening the reporting of observational studies in epidemiology (STROBE) statement: Guidelines for reporting observational studies. Equator Network (2023, accessed 18 Jan 2023). https://www.equator-network.org/reporting-guidelines/strobe/.
Tong, A. et al. Core outcome measures for trials in people with coronavirus disease 2019: Respiratory failure, multiorgan failure, shortness of breath, and recovery. Crit. Care Med. 49, 503516. https://doi.org/10.1097/CCM.0000000000004817 (2021).
Article PubMed PubMed Central Google Scholar
OHoro, J. C. et al. Outcomes of COVID-19 with the Mayo Clinic model of care and research. Mayo Clin. Proc. 96, 601618. https://doi.org/10.1016/j.mayocp.2020.12.006 (2021).
Article CAS PubMed Google Scholar
OShaughnessy, J. Revised Letter of Authorization (2021, accessed 9 Nov 2023). https://www.fda.gov/media/141477/download.
Jeny, F. et al. Correspondence on glucocorticoid-induced relapse of COVID-19 in a patient with sarcoidosis. Ann. Rheum. Dis. 81, e241. https://doi.org/10.1136/annrheumdis-2020-218957 (2022).
Article PubMed Google Scholar
Kim, M. S., An, M. H., Kim, W. J. & Hwang, T. H. Comparative efficacy and safety of pharmacological interventions for the treatment of COVID-19: A systematic review and network meta-analysis. PLoS Med. 17, e1003501. https://doi.org/10.1371/journal.pmed.1003501 (2020).
Article CAS PubMed PubMed Central Google Scholar
Rubio-Rivas, M. et al. WHO ordinal scale and inflammation risk categories in COVID-19. Comparative study of the severity scales. J. Gen. Intern. Med. 37, 19801987. https://doi.org/10.1007/s11606-022-07511-7 (2022).
Article PubMed PubMed Central Google Scholar
R Core Team. R: A language and environment for statistical computing. R Foundation for statistical computing, Vienna, Austria (2020, accessed 18 Jan 2023). https://www.R-project.org/.
Smith, J. B., Gonzales, E. G., Li, B. H. & Langer-Gould, A. Analysis of rituximab use, time between rituximab and SARS-CoV-2 vaccination, and COVID-19 hospitalization or death in patients with multiple sclerosis. JAMA Netw. Open 5, e2248664. https://doi.org/10.1001/jamanetworkopen.2022.48664 (2022).
Article PubMed PubMed Central Google Scholar
Levavi, H., Lancman, G. & Gabrilove, J. Impact of rituximab on COVID-19 outcomes. Ann. Hematol. 100, 28052812 (2021).
Article CAS PubMed PubMed Central Google Scholar
Booth, S. et al. Key findings from the UKCCMP cohort of 877 patients with haematological malignancy and COVID-19: Disease control as an important factor relative to recent chemotherapy or anti-CD20 therapy. Br. J. Haematol. 196, 892901 (2021).
Article PubMed PubMed Central Google Scholar
McKay, K. A. et al. Rituximab infusion timing, cumulative dose, and hospitalization for COVID-19 in persons with multiple sclerosis in Sweden. JAMA. Netw. Open. 4, e2136697. https://doi.org/10.1001/jamanetworkopen (2021).
Article PubMed PubMed Central Google Scholar
Misset, B. et al. Convalescent plasma for Covid-19-induced ARDS in mechanically ventilated patients. NEJM 389, 15901600 (2023).
Article CAS PubMed Google Scholar
Levine, A. C. et al. COVID-19 convalescent plasma outpatient therapy to prevent outpatient hospitalization: A meta-analysis of individual participant data from five randomized trials. Clin. Infect. Dis. 76, 20772086 (2023).
Article PubMed PubMed Central Google Scholar
Ripoll, J. G. et al. Vaccine-boosted convalescent plasma therapy for patients with immunosuppression and COVID-19. Blood Adv. 6, 59515955 (2022).
Article CAS PubMed PubMed Central Google Scholar
Cook, L. B. et al. Third primary SARS-CoV-2 mRNA vaccines enhance antibody responses in most patients with haematological malignancies. Nat Commun. 13, 6922. https://doi.org/10.1038/s41467-022-34657-z (2022).
Article ADS CAS PubMed PubMed Central Google Scholar
Trottier, C. A. et al. Dual antiviral therapy for persistent coronavirus disease 2019 and associated organizing pneumonia in an immunocompromised host. Clin. Infect. Dis. 76, 923925 (2023).
Article PubMed Google Scholar
Read more from the original source:
COVID-19 outcome is not affected by anti-CD20 or high-titer ... - Nature.com
Recommendation and review posted by G. Smith
